Skip to content

US · PHG · MEDICAL - DEVICES

Koninklijke Philips N.V. (PHG) intrinsic value and stock valuation

$28.61as of 2026-11-21 · Mkt cap 25.99B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Koninklijke Philips N.V. DCF and intrinsic value

InvestorsCraft values PHG with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from PHG’s statements →

Koninklijke Philips N.V. Graham Number

Graham Number: $15.46d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Devices Amsterdam, NH 1077 WV philips.ca

How the business is doing

Fiscal 2011–2025, USD

Revenue
$17.8B+0.6% 5y CAGRd
20112025
Net income
$895M-5.5% 5y CAGRd
20112025
Free cash flow
$893M-16.2% 5y CAGRd
20112025
Total equity
$11B-1.6% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$17.8B$18B$18.2B$17.8B$17.2B
Operating income$1.42B$529M-$-115M-$-1.53B$553M
Net income$895M-$-702M-$-466M-$-1.61B$3.32B
EPSd$929.9K-$-752.11K-$-491.15K-$-1.69M$3.49M
Operating cash flow$1.16B$1.7B$2.31B-$-181.82M$1.93B
Capital expenditure-$-269M-$-342.9M-$-371.9M-$-466.63M-$-469.25M
Free cash flow$893M$1.35B$1.94B-$-648.45M$1.46B
Total assets$26.9B$29B$29.4B$30.7B$31B
Total debt$8.09B$7.49B$7.29B$7.34B$6.05B
Net debt$5.29B$5.09B$5.42B$6.17B$3.74B
Total equity$11B$12B$12.1B$13.3B$14.5B
Cash and short-term investments$2.79B$2.4B$1.87B$1.18B$2.31B
Income statement
20252024202320222021
Revenue$17.8B$18B$18.2B$17.8B$17.2B
Cost of revenue$9.78B$10.2B$10.7B$10.6B$9.99B
Gross profit$8.06B$7.77B$7.45B$7.19B$7.17B
Research and development expenses$1.7B$1.75B$1.89B$2.09B$1.81B
Selling, general and administrative expenses$4.97B$5.07B$5.13B$5.29B$4.86B
Other expenses-$-36M$429M$541M$1.34B-$-48M
Operating expenses$6.63B$7.24B$7.56B$8.72B$6.62B
Cost and expenses$16.4B$17.5B$18.3B$19.4B$16.6B
Interest income$108.5M$79M$46M$25M$18M
Interest expense$332.3M$337M$306M$244M$164M
Depreciation and amortization$1.13B$1.39B$1.26B$1.6B$1.32B
Ebitda$2.64B$1.85B$1.04B$115M$2B
Operating income$1.42B$529M-$-115M-$-1.53B$553M
Total other income/expenses, net-$-242M-$-406M-$-412M-$-202M-$-44M
Income before tax$1.18B$123M-$-527M-$-1.73B$509M
Income tax expense$282M$963M-$-73M-$-113M-$-103M
Net income$895M-$-702M-$-466M-$-1.61B$3.32B
Weighted average shares outstanding$962.4M$933.4M$948.8M$952.5M$907.5M
Weighted average diluted shares outstanding$962.5M$933.4M$948.8M$952.5M$950.3M
Balance sheet
20252024202320222021
Cash and short-term investments$2.79B$2.4B$1.87B$1.18B$2.31B
Net receivables$3.53B$3.67B$4.25B$4.65B$4.29B
Inventory$2.87B$3.2B$3.49B$4.05B$3.45B
Total current assets$9.93B$10B$9.94B$10.3B$10.3B
Property, plant and equipment, net$2.22B$2.45B$2.48B$2.64B$2.7B
Goodwill and intangible assets$11.8B$13.4B$13.1B$13.8B$14.3B
Long-term investments$852M$889M$1B$1.2B$1.06B
Total non-current assets$17B$19B$19.5B$20.4B$20.6B
Total assets$26.9B$29B$29.4B$30.7B$31B
Accounts payable$1.93B$1.83B$1.92B$1.97B$1.87B
Short-term debt$1.15B$443M$334M$325M$310M
Deferred revenue$0.00$1.7B$1.81B$1.7B$1.49B
Total current liabilities$7.51B$8.14B$8.29B$7.93B$7.45B
Long-term debt$6.93B$7.05B$6.96B$7.02B$5.74B
Deferred revenue, non-current$0.00$431M$469M$515M$446M
Total non-current liabilities$8.45B$8.79B$9.06B$9.47B$9.04B
Capital lease obligations$0.00$1.07B$1.08B$1.08B$1.22B
Total liabilities$16B$16.9B$17.3B$17.4B$16.5B
Common stock$193M$188M$183M$178M$177M
Retained earnings$3.58B$3.65B$5.4B$6.83B$9.34B
Accumulated other comprehensive income (loss)$274M$1.93B$879M$1.49B$748M
Total equity$11B$12B$12.1B$13.3B$14.5B
Total investments$852M$891M$1B$1.21B$1.06B
Total debt$8.09B$7.49B$7.29B$7.34B$6.05B
Net debt$5.29B$5.09B$5.42B$6.17B$3.74B
Cash flow statement
20252024202320222021
Net income$895M-$-912.95M-$-492.99M-$-1.7B$718.6M
Depreciation and amortization$1.13B$1.26B$1.39B$1.26B$1.24B
Stock-based compensation$141M$0.00$0.00$0.00$0.00
Change in working capital-$-1.33B$7.57M$1.51B-$-1.24B-$-179.66M
Accounts receivable-$-9M-$-1.08M$322.2M-$-359.43M$0.00
Inventory-$-115M$248.8M$277.9M-$-601.16M-$-686.73M
Accounts payable$0.00-$-630.63M$387M$54.7M$258.9M
Net cash provided by operating activities$1.16B$1.7B$2.31B-$-181.82M$1.93B
Investments in property, plant and equipment-$-269M-$-731.22M-$-695.16M-$-847.09M-$-901.85M
Acquisitions, net-$-3M$141.7M$104.9M-$-600.11M-$-3.5B
Net cash used for investing activities-$-737M-$-633.87M-$-553.53M-$-1.58B-$-317.95M
Common stock issued$0.00$0.00$0.00$12.6M$27.2M
Common stock repurchased$0.00-$-444.57M-$-715.7M-$-196.53M-$-1.93B
Dividends paid-$-328M-$-1.08M-$-2.16M-$-433M-$-569.71M
Net cash used for financing activities$107M-$-536.52M-$-916.79M$525.5M-$-2.77B
Net change in cash$393M$421.6M$813.8M-$-1.37B-$-1.33B
Cash at end of period$2.79B$2.49B$2.06B$1.25B$2.62B
Operating cash flow$1.16B$1.7B$2.31B-$-181.82M$1.93B
Capital expenditure-$-269M-$-342.9M-$-371.9M-$-466.63M-$-469.25M
Free cash flow$893M$1.35B$1.94B-$-648.45M$1.46B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Koninklijke Philips N.V.

        Koninklijke Philips NV is a technology company, which engages in the healthcare, lighting, and consumer well-being markets. It operates through the following segments: Diagnosis and Treatment; Connected Care; Personal Health; and Other. The Diagnosis and Treatment segment consists of systems, smart devices, software, and services, powered by AI-enabled solutions that support precision diagnoses and minimally invasive treatment in therapeutic areas such as cardiology, peripheral vascular, neurology, surgery, and oncology. The Connected Care segment focuses on Hospital Patient Monitoring, Sleep and Respiratory Care, and Enterprise Informatics. The Personal Health segment represents Oral Healthcare business unit, Personal Care business unit, and Mother and Child Care business unit. The Other segment is involved on the Innovation and Strategy, IP Royalties, Central costs, and other small items. The company was founded by Anton Frederik Philips and Gerard Leonard Frederik Philips in 1891 and is headquartered in Amsterdam, the Netherlands.

        CEO
        Roy Jakobs
        Employees
        66.4K
        Beta
        0.92

        Explore

        Frequently asked questions

        What is the intrinsic value of Koninklijke Philips N.V. (PHG)?

        Koninklijke Philips N.V. (PHG) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is PHG undervalued?

        PHG trades at a price of $28.61 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.